Literaturverzeichnis 2017 / 2018


Hier finden Sie die Literaturangaben zu den Übersichtsartikeln der Zeitschrift für Infektionstherapie aus den Jahren 2017 und 2018




Heft 6 / 2018

Heft 5 / 2018

Heft 4 / 2018

Heft 3 / 2018

Heft 2 / 2018

Heft 1 / 2018


Heft 6 / 2017

Heft 3 / 2017

Heft 2 / 2017

Heft 1 / 2017


Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2018 der Zeitschrift für Infektionstherapie


Impfungen im Alter


1. Esposito S et al.. Vaccination of 50+ adults to promote healthy ageing in Europe: The way forward. Vaccine. 2018 Sep 18;36(39):5819-5824.

doi:10.1016/j.vaccine.2018.08.041. Epub 2018 Aug 22. Review. PubMed PMID: 30143273.


2. Wagner A et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep. 2018 Jun 29;8(1):9825. doi: 10.1038/s41598-018-28111-8. PubMed PMID: 29959387; PubMed Central PMCID: PMC6026142.


3. Agarwal D, Schmader KE, Kossenkov AV, Doyle S, Kurupati R, Ertl HCJ. Immune response to influenza vaccination in the elderly is altered by chronic medication use. Immun Ageing. 2018 Aug 31;15:19. doi: 10.1186/s12979-018-0124-9. eCollection 2018. PubMed PMID: 30186359; PubMed Central PMCID: PMC6119322.


4. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):119-23. PubMed PMID: 23425960; PubMed Central PMCID: PMC4604884.


5. Lode HM, Stahlmann R. [Vaccinations in respiratory medicine]. HNO. 2015 Sep;63(9):649-59; quiz 659-60. doi: 10.1007/s00106-015-0058-x. German. PubMed PMID: 26330051.


6. STIKO Epid Bull 2018; 383-386


7. Wutzler P, Hardt R, Knuf M, Wahle K. Targeted vaccine selection in influenza vaccination. Dtsch Arztebl Int. 2013 Nov 22;110(47):793-8. doi: 10.3238/arztebl.2013.0793. Review. PubMed PMID: 24314622; PubMed Central PMCID: PMC3859908.


8. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep. 2018 Aug 24;67(3):1-20. doi: 10.15585/mmwr.rr6703a1. PubMed PMID: 30141464; PubMed Central PMCID: PMC6107316.


9. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189-202. doi: 10.1146/annurev-med-120611-145115. Review. PubMed PMID: 23327522.


10. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012 Jan;67(1):71-9.

doi: 10.1136/thx.2009.129502. Epub 2010 Aug 20. Review. PubMed PMID: 20729232.


11. Pletz MW et al. The Burden of Pneumococcal Pneumonia – Experience of the German Competence Network CAPNETZ. Pneumologie 2012; 66(08): 470-475


12. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on community-acquired pneumonia in 388 406 ???? patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009 Dec;64(12):1062-9. doi:10.1136/thx.2008.109785. Epub 2009 May 18. PubMed PMID: 19454409; PubMed Central PMCID: PMC2782114.


13. Imöhl M, van der Linden M. [Invasive pneumococcal disease in Germany in the era of pneumococcal conjugate vaccination]. Dtsch Med Wochenschr. 2014 Jun;139(25-26):1346-51. doi: 10.1055/s-0034-1370126. Epub 2014 Jun 10. German.

PubMed PMID: 24914512.


14. STIKO, Epidem Bull 2016;36:351-383


15. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen vom 02.09.1993; Stand: 01.01.2018


16. Ewig S et al. [Management of Adult Community-acquired Pneumonia and Prevention - Update 2016]. Pneumologie. 2016 Mar;70(3):151-200.

doi: 10.1055/s-0042-101873. Epub 2016 Feb 29. German. PubMed PMID: 26926396.


17. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9.

doi: 10.1111/1469-0691.12320. Review. PubMed PMID: 24083785.


18. Clutterbuck EA et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012 May 1;205(9):1408-16 FREE FULL TEXT


19. Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, Spoulou VS. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. J Infect Dis. 2018 Jun 5;218(1):26-34


20. Fätkenheuer G, Kwetkat A, Pletz MW, Schelling J, Schulz RJ, van der Linden M, Welte T. [Prevention in the elderly: position paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany]. Z Gerontol Geriatr. 2014 Jun;47(4):302-9


21. Bonten MJ et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114-25 FREE FULL TEXT


22. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):944-7 FREE FULL TEXT 


23. Riffelmann M, Wirsing von König CH. [Lifelong protection against pertussis]. Dtsch Med Wochenschr. 2009 Apr;134 Suppl 2:S86-9


24. Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered  concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial. Vaccine. 2013 Mar 1;31(11):1496-502


25. Tseng HF et al. Vaccine Safety Datalink (VSD) Team. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013 Feb;56(3):315-21


26. Esposito S et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94 FREE FULL TEXT



27. STIKO Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut – 2018/2019. Epidem Bull 2018;34:335-382 PDF-DATEI


28. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352:2266-7


29. Wutzler P. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?]. Dtsch Med Wochenschr. 2009 Apr;134 Suppl 2:S90-4


30. Dooling KL et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108 FREE FULL TEXT




Literaturangaben zum Übersichtsartikel aus

Heft 5 / 2018 der Zeitschrift für Infektionstherapie


Harnwegsinfektionen beim Mann - welche Antibiotika und wie lange behandeln?


1. Schaeffer AJ, Nicolle LE. Urinary Tract Infections in Older Men. N Engl J Med. 2016 Feb 11;374(6):562-71 Review.


2. Ulleryd P et al. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int. 1999 Sep;84(4):470-4


3. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949-56


4. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Ceftazidime-avibactam versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016 Sep 15;63(6):754-762.



5. Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018 Apr;78(6):675-692


6. Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-9


7. Drekonja DM et al. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013 Jan 14;173(1):62-8


8. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22


9. Mospan GA, Wargo KA. 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI). J Am Board Fam Med. 2016 11/12;29(6):654-662


10. van Nieuwkoop C et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017 Apr 3;15(1):70 FREE FULL TEXT




Literaturangaben zum Übersichtsartikel aus

Heft 4 / 2018 der Zeitschrift für Infektionstherapie


Antibiotika in der Zahnmedizin

1. Schwabe U et al.

Arzneiverordnungs-Report 2015, Springer Verlag Stuttgart 2016


2. Schwabe U et al.

Arzneiverordnungs-Report 2016, Springer Verlag Stuttgart 2017


3. Abu-Ta'a M, Quirynen M, Teughels W, van Steenberghe D. Asepsis during periodontal surgery involving oral implants and the usefulness of peri-operative antibiotics: a prospective, randomized, controlled clinical trial. J Clin Periodontol. 2008 Jan;35(1):58-63


4. Podbielski A, Pahncke D, Mittelmeier W. [Antibiotic prophylaxis for patients with joint prostheses undergoing dental treatment--a topic for discussion]. Z Orthop Unfall. 2009 May-Jun;147(3):350-5


5. Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J, Medina Henríquez J, Lockhart PB, Chu VH, Diz Dios P. Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. J Antimicrob Chemother. 2016 Jul;71(7):2022-30


6. Darouiche RO. Antimicrobial approaches for preventing infections associated with surgical implants. Clin Infect Dis. 2003 May 15;36(10):1284-9


7. López-Píriz R, Aguilar L, Giménez MJ. Management of odontogenic infection of pulpal and periodontal origin. Med Oral Patol Oral Cir Bucal. 2007 Mar 1;12(2):E154-9


8. Aravena PC, Oyarzún CP, Arias MF, Monardes H, Jerez A, Benso B. Single-Dose Bioavailability for Prophylactic Coverage in Patients Undergoing Dental Implant Surgery. Int J Oral Maxillofac Implants. 2018 Mar/Apr;33(2):419-424


9. Binahmed A, Stoykewych A, Peterson L. Single preoperative dose versus long-term prophylactic antibiotic regimens in dental implant surgery. Int J Oral Maxillofac Implants. 2005 Jan-Feb;20(1):115-7


10. Esposito M, Grusovin MG, Loli V, Coulthard P, Worthington HV. Does antibiotic prophylaxis at implant placement decrease early implant failures? A Cochrane systematic review. Eur J Oral Implantol. 2010 Summer;3(2):101-10


11. Ahmad N, Saad N. Effects of antibiotics on dental implants: a review. J Clin Med Res. 2012 Feb;4(1):1-6. FREE FULL TEXT


12. Arduino PG, Tirone F, Schiorlin E, Esposito M. Single preoperative dose of prophylactic amoxicillin versus a 2-day postoperative course in dental implant surgery: A two-centre randomised controlled trial. Eur J Oral Implantol. 2015 Summer;8(2):143-9


13. Surapaneni H, Yalamanchili PS, Basha MH, Potluri S, Elisetti N, Kiran Kumar MV. Antibiotics in dental implants: A review of literature. J Pharm Bioallied Sci. 2016 Oct;8(Suppl 1):S28-S31. Review. FREE FULL TEXT


14. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ. 2008 Apr 5;336(7647):770-1 FREE FULL TEXT


15. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015 Mar 28;385(9974):1219-28 FREE FULL TEXT


16. Tubiana S, Blotière PO, Hoen B, Lesclous P, Millot S, Rudant J, Weill A, Coste J, Alla F, Duval X. Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. BMJ. 2017 Sep 7;358:j3776 FREE FULL TEXT


17. Habib G. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-3128


18. Rademacher WMH, Walenkamp GHIM, Moojen DJF, Hendriks JGE, Goedendorp TA, Rozema FR. Antibiotic prophylaxis is not indicated prior to dental procedures for prevention of periprosthetic joint infections. Acta Orthop. 2017 Oct;88(5):568-574 FREE FULL TEXT


19. Rostetter C, Schenkel J, Rücker M, Lübbers HT. Amoxicillin mit Clavulansäure. Standardantibiotikum im allgemeinzahnärztlichen Alltag. Swiss Dent J. 2017;127(7-8):654-655


20. Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother. 2015 Aug;70(8):2382-8 FREE FULL TEXT




Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2018 der Zeitschrift für Infektionstherapie


Proteinbindung von Antibiotika -

inaktivierende und antibakterielle Wirkungen


1. Davis BD. Binding of sulfonamides by plasma proteins. Science 1942;95:78


2. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983 Mar;11(3):233-8


3. Dalhoff A. Seventy-Five Years of Research on Protein Binding. Antimicrob Agents Chemother 2018;62. pii: e01663-17.


4. Silverman JA, Mortin LI, Vanpraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149–2152


Literaturangaben zum Übersichtsartikel aus

Heft 1 / 2018 der Zeitschrift für Infektionstherapie

Entwicklung neuer Antibiotika - wo geht die Reise hin?

1. Theuretzbacher U. Antibiotic innovation for future public health needs. Clin Microbiol Infect. 2017 Oct;23(10):713-717.


2. O'Dwyer K et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98 FREE FULL TEXT


3. Tacconelli E et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Inf Dis 2017 (online, 21. Dezember 2017) PubMed abstract


4. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017 Oct;23(10):704-712 PubMed abstract


5. Torres A et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Inf Dis 2017 (15. Dezember 2017, online) PubMed abstract


6. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17 PubMed abstract


7. Ito A et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01454-17 FREE FULL TEXT


8. Tillotson GS. Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infect Dis (Auckl). 2016 Oct 11;9:45-52. FREE FULL TEXT


Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2017 der Zeitschrift für Infektionstherapie

Inhalative Antibiotika: Stellenwert bei Infektionen der tiefen Atemwege

1: Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014 Mar;11(3):425-34 FREE FULL TEXT


2: Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan  7;340(1):23-30 FREE FULL TEXT


3: Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev. 2016 Jul;29(3):581-632 FREE FULL TEXT


4: Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec;6(1):35 FREE FULL TEXT


5: Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May;42(5):1915-22 FREE FULL TEXT


6: Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71


7: Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014 Aug;44(2):382-93 FREE FULL TEXT


8: Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):481-5


9: Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014 Apr 15;189(8):975-82 FREE FULL TEXT


10: Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013 Sep;68(9):812-7 FREE FULL TEXT



11: Insmed, Inc. TR02-107 trialreport.

Available from:


12: Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013 May;41(5):1107-15 FREE FULL TEXT


13: De Soyza A et al. Late-Breaking-Abstract: Respire I  Europ Respir J 2016; 48, Suppl 60


14: Aradigm Corporation: Memorandum July 27, 2017


15: Kollef MH, Micek ST. Recommendations for aerosolized antibiotics in ventilator-associated pneumonia and ventilator-associated tracheobronchitis: too  little and too late? Clin Microbiol Infect. 2017 Sep;23(9):593-595


16: Solé-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, Luyt CE, Pereira JM, Riera J, Felton T, Dhanani J, Welte T, Garcia-Alamino JM, Roberts JA, Rello J. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis. Anesthesiology. 2017 May;126(5):890-908


17: Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, Riera J, Vos  MC, Monsel A, Dhanani J, Roberts JA. Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect.  2017 Sep;23(9):640-646


18: Kollef M H et al. Chest 2017, in press


19: Niederman MS(1), Chastre J, Corkery K, Fink JB, Luyt CE, García MS.BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71


20: Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J, Palmer LB, Pereira JM, Felton T, Dhanani J, Bassetti M, Welte T, Roberts JA. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European  Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2017 Sep;23(9):629-639


Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2017 der Zeitschrift für Infektionstherapie

Therapie von Helicobacter pylori-Infektionen

1. Warren JR Helicobacter: the ease and difficulty of a new discovery (Nobel lecture). ChemMedChem. 2006;1:672-85


2. Hentschel E et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-12 FREE FULL TEXT


3. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239


4. Fischbach W S2k-Leitllinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol. 2016 Apr;54(4):327-63


5. Wüppenhorst N et al. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother. 2014;69:3127-33


6. Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter. 2017;22:e12327


7. Best LM et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother. 2003 Oct;47(10):3138-44 FREE FULL TEXT


8. Malfertheiner P et al. . Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13


9. Greenberg ER et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507-14 FREE FULL TEXT


10. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs. 2017 May;77(7):765-776


Literaturangaben zum Übersichtsartikel aus

Heft 2 / 2017 der Zeitschrift für Infektionstherapie

Antiinfektive Therapie der Sepsis

1: Seymour CW, Liu VX, Iwashyna TJ et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):762-74


2: Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552


3: Panknin HT, Müller-Werdan U, Schröder S. Neue Sepsisdefinition. ProCare. 2016 Oct;21(8):22-5


4: Zhang D, Micek ST, Kollef MH. Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. Crit Care Med. 2015 Oct;43(10):2133-40


5: Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med.  2010 Jun;36(6):979-83


6: van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA,  Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008 Sep;23(3):422-30


7: Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91


8: Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090


Literaturangaben zum Übersichtsartikel aus

Heft 1 / 2017 der Zeitschrift für Infektionstherapie

Optimale Dauer der Antibiotikatherapie – eine aktuelle Bestandsaufnahme

1. Armand-Lefèvre L et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488-95 FREE FULL TEXT


2. Rice LB The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008;46:491-496


3. Spellberg B The New Antibiotic Mantra-"Shorter Is Better". JAMA Intern Med. 2016;176:1254-1255


4. Uranga A et al.  Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176:1257-1265


5. Choudhury G et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia-a propensity-adjusted analysis. Clin Microbiol Infect. 2011;17:1852-1858.


6. Dimopoulos G, Matthaiou DK. Duration of therapy of ventilator-associated pneumonia. Curr Opin Infect Dis. 2016;29:218-222


7. Sawyer RG et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996-2005 FREE FULL TEXT



8. Bernard L et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385:875-882


9. Lora-Tamayo J, Murillo O Shorter treatments for vertebral osteomyelitis. Lancet 2015;385:836-837


10. Hoberman A et al. Shortened antimicrobial treatment for acute otitis media in young children. N Engl J Med. 2016 Dec 22;375:2446-2456 FREE FULL TEXT.


Informationen für Ärzte und Apotheker zur rationalen Infektionstherapie

Die Zeitschrift für Infektionstherapie (bis 2015: "Zeitschrift für Chemo-therapie") erscheint im Jahr 2018 im 39. Jahrgang. Herausgeber und Redaktion sind bemüht, Sie kontinu-ierlich und aktuell über wichtige Entwicklungen im Bereich der Infektionstherapie zu informieren.


Die vollständigen, aktuellen Ausgaben der Zeitschrift sind nur im Abonnement erhältlich.


Nach 24 Monaten stehen die Hefte als PDF-Dateien  frei zur Verfügung (Frühere Ausgaben und Register).


Wir bieten Ihnen auf diesem Wege ebenfalls alle Artikel der Rubrik "Neueinführungen" und einige andere regelmäßige Beiträge aus der Zeitschrift an.


Letzte Aktualisierung dieser Seiten:

16. November 2018

Druckversion Druckversion | Sitemap
© Zeitschrift für Infektionstherapie